Search Tag: Radiopharmaceutical

Executive Health Management

2022 04 Oct

Dr. Puhlmann has over 20 years of oncology drug development experience and has spearheaded the global development and approval of multiple cancer drugs Viewpoint Molecular Targeting, Inc, a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents announced the...Read more